Ascentage Pharma (Suzhou) Co. Ltd. and China Pharmaceutical University have identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Scientists at East China Normal University and East China University of Science & Technology have synthesized 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting cadherin-17 (CDH17) linked to a cytotoxic drug through a linker.
Orthoflaviruses such as dengue, West Nile and Zika viruses are a threat to public health for which no specific treatments exist. Their protease NS2B-NS3, also called orthoflavivirin, is an attractive drug target because it is essential for virus maturation. Targeting viral proteases has already proven effective for creating drugs against HIV, hepatitis C and SARS-CoV-2 viruses.
Researchers from Wuhan Institute of Biomedical Sciences, Jianghan University and collaborators recently showed that activating the endogenous transcription factors Ngn2 and Isl1 via CRISPRa can directly reprogram astrocytes into functional motor neurons in the mouse spinal cord.
Peptidream Inc. has announced approval of a clinical research protocol for [64Cu]PD-29875, a Claudin 18.2-targeting 64Cu-labeled radiopharmaceutical, in patients with gastric cancer.
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Astrazeneca plc has provided data for their CD22-targeting antibody-drug conjugate (ADC) AZD-4512 under development for the treatment of B-cell malignancies, which still have significant rates of disease resistance and relapse, as well as treatment-related toxicities.
Indupro Inc. has announced a strategic equity investment and research collaboration with Sanofi SA. The agreement with Sanofi includes the right of first negotiation for Indupro’s bispecific PD-1 agonist program.
Absci Corp. has released new preclinical data for ABS-201, an AI-designed antibody targeting the prolactin receptor (PRLR) designed to stimulate hair follicle regeneration and promote durable hair regrowth for the potential management of androgenetic alopecia.
RSS
